Personal information

Other IDs

Loop profile: 96320

Activities

Collapse all

Education and qualifications (1)

Karolinska Institutet: Stockholm, SE

2017-03-01 to present | Professor (Department of clinical science and education)
Education
Source: Self-asserted source
Thomas Nyström

Works (13)

Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk

Diabetes, Obesity and Metabolism
2024-10 | Journal article
DOI: 10.1111/dom.15696
Contributors: Thomas Nyström
Source: check_circle
Crossref

Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials

Diabetologia
2024-08 | Journal article
DOI: 10.1007/s00125-024-06151-2
Contributors: Sofia Sterner Isaksson; Henrik Imberg; Irl B. Hirsch; Erik Schwarcz; Jarl Hellman; Magnus Wijkman; Jan Bolinder; Thomas Nyström; Helene Holmer; Sara Hallström et al.
Source: check_circle
Crossref

The need for registry‐based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post‐stroke outcome

Diabetes, Obesity and Metabolism
2024-07 | Journal article
DOI: 10.1111/dom.15577
Contributors: Vladimer Darsalia; Ellen Vercalsteren; Dimitra Karampatsi; Mihaela Oana Romanitan; Michael V. Mazya; Thomas Nyström; Cesare Patrone
Source: check_circle
Crossref

Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes

Diabetes, Obesity and Metabolism
2024-06 | Journal article
DOI: 10.1111/dom.15545
Contributors: Thomas Nyström; Mikael Andersson Franko; Johnny Ludvigsson; Marcus Lind; Martina Persson
Source: check_circle
Crossref

Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8)

Journal of Diabetes Science and Technology
2024-01 | Journal article
DOI: 10.1177/19322968221101916
Contributors: Thomas Nyström; Erik Schwarz; Sofia Dahlqvist; Magnus Wijkman; Magnus Ekelund; Helen Holmer; Jan Bolinder; Jarl Hellman; Henrik Imberg; Irl B. Hirsch et al.
Source: check_circle
Crossref

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study

Diabetes, Obesity and Metabolism
2023-01 | Journal article
DOI: 10.1111/dom.14870
Contributors: Thomas Nyström; Emilie Toresson Grip; Joel Gunnarsson; Paula Casajust; Kristina Karlsdotter; Josefin Skogsberg; Anastasia Ustyugova
Source: check_circle
Crossref

LDL cholesterol level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes mellitus: A nationwide cohort study

Journal of Internal Medicine
2021-06 | Journal article
DOI: 10.1111/joim.13212
Contributors: B. Rathsman; J. Haas; M. Persson; J. Ludvigsson; A.‐M. Svensson; M. Lind; M. Andersson Franko; T. Nyström
Source: check_circle
Crossref

Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors

PLOS ONE
2021-06-30 | Journal article
DOI: 10.1371/journal.pone.0254079
Contributors: Göran Bratt; Graciela Andrei; Johanna Brännström; Catharina Missalidis; Thomas Nyström
Source: check_circle
Crossref

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study

Diabetes Care
2021-05-01 | Journal article
DOI: 10.2337/dc20-2839
Contributors: Robin Kristófi; Johan Bodegard; Anna Norhammar; Marcus Thuresson; David Nathanson; Thomas Nyström; Kåre I. Birkeland; Jan W. Eriksson
Source: check_circle
Crossref

Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study

Diabetes, Obesity and Metabolism
2020-02 | Journal article
DOI: 10.1111/dom.13885
Contributors: Alexander Zabala; Vladimer Darsalia; Martin J. Holzmann; Stefan Franzén; Ann‐Marie Svensson; Björn Eliasson; Cesare Patrone; Thomas Nyström; Magnus Jonsson
Source: check_circle
Crossref

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study

Diabetes, Obesity and Metabolism
2019-05 | Journal article
DOI: 10.1111/dom.13627
Contributors: Anna Norhammar; Johan Bodegård; Thomas Nyström; Marcus Thuresson; David Nathanson; Jan W. Eriksson
Source: check_circle
Crossref

Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study

Endocrinology, Diabetes & Metabolism
2019-04 | Journal article
DOI: 10.1002/edm2.58
Contributors: Thomas Nyström; Irene Santos‐Pardo; Xin Fang; Yang Cao; Fredric Hedberg; Johan Jendle
Source: check_circle
Crossref

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10

Diabetes Care
2018-06-01 | Journal article
DOI: 10.2337/dc18-0339
Contributors: Thomas Nyström; Johan Bodegård; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W. Eriksson
Source: check_circle
Crossref
How many people are using ORCID?